PRECEDE study points to screening method for pancreatic cancer

Researchers identify novel molecular target for pancreatic cancer

Researchers at City of Hope have identified a new molecular target for treating pancreatic cancer, reports a Gastroenterologystudy published on April 8.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Gene-based blood test for melanoma may detect early signs of cancer return

Monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer recurrence, a recent study led by researchers at NYU Langone Health and its Perlmutter Cancer Center shows.

April 18, 2025

Vol.51 No.15

Clinical Roundup

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice, according to results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

April 04, 2025

Vol.51 No.13

Drugs & Targets

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Exact Sciences Corp. announced the launch of Cologuard Plus, the most accurate noninvasive colorectal cancer screening test reported in studies to date. FDA-approved for average-risk patients 45+ and covered by Medicare, the Cologuard Plus test detects 95% of colorectal cancers at 94% specificity in the U.S. screening population.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

Two recent studies by researchers from Regenstrief Institute and the Indiana University School of Medicine explore the effect of the pandemic on colorectal cancer screening tests and diagnostic colonoscopies in central Indiana.

March 28, 2025

Vol.51 No.12

Drugs & Targets

FDA approves cabozantinib for patients 12 and up with pNET and epNET

FDA approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.

March 28, 2025

Vol.51 No.12

PRECEDE study points to screening method for pancreatic cancer

YOU MAY BE INTERESTED IN

Researchers identify novel molecular target for pancreatic cancer

Gene-based blood test for melanoma may detect early signs of cancer return

Targeting FGFR2 may prevent or delay some KRAS-mutated pancreatic cancers

Exact Sciences launches the Cologuard Plus test for colorectal cancer screening

Pandemic caused temporary disruptions in CRC screening and minimal impact on diagnosis, two studies show

FDA approves cabozantinib for patients 12 and up with pNET and epNET

Renew today!

Subscriber content

Never miss an issue!

Login